Societe Generale’s VanEck Biotech ETF BBH Stock Holding History

Societe Generale’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$414K	Buy	+4,041	New	+$431K	﹤0.01%	1802

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Societe Generale's BBH Position: Q2 2016 in Review

Societe Generale opened a new position in VanEck Biotech ETF (BBH) in Q2 2016: 4,041 shares worth $414K. The stake represents ﹤0.01% of the portfolio and ranks #1802 among its holdings.

78 funds tracked by Wall St. Rank hold BBH as of Q2 2016.

Societe Generale held 4,041 shares of VanEck Biotech ETF worth $414K as of Q2 2016.
VanEck Biotech ETF was a new Societe Generale position in Q2 2016.
VanEck Biotech ETF made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1802 holding.
78 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.